Advanced cardiovascular risk prediction in the emergency department: updating a clinical prediction model – a large database study protocol

Autor: Richard Body, Anthony M. Heagerty, Evangelos Kontopantelis, David A Jenkins, Anisa Jabeen Nasir Jafar, Glen P. Martin, Brian McMillan, Charles Reynard, Rajendar Garlapati

Publikováno v: Diagnostic and Prognostic Research, Vol 5, Iss 1, Pp 1-7 (2021)
Diagnostic and Prognostic Research
Reynard, C, Martin, G P, Kontopantelis, E, Jenkins, D A, Heagerty, A, McMillan, B, Jafar, A, Garlapati, R & Body, R 2021, ' Advanced cardiovascular risk prediction in the emergency department : updating a clinical prediction model-a large database study protocol ', Diagnostic and Prognostic Research, vol. 5, no. 1 . https://doi.org/10.1186/s41512-021-00105-7

Background Patients presenting with chest pain represent a large proportion of attendances to emergency departments. In these patients clinicians often consider the diagnosis of acute myocardial infarction (AMI), the timely recognition and treatment

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1590f3bdcd8c94f20ed53647334c01e
https://doaj.org/article/16a98c1acec94964a873bb8f962826fa

Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial

Autor: Ruth Knight, Jonathan Underwood, Joanna Black, Maisha Jabeen, Fleur Cantle, Susan J Dutton, Timothy S. C. Hinks, James F. Melhorn, Phil Moss, Ariel Wang, Sophie B. Morgan, Duncan Richards, Jennifer L Cane, Graham Johnson, Vicki S Barber, David Clarke, Rajendar Garlapati, Samer Elkhodair, Ian D. Pavord, Lucy Cureton, Daniel Lasserson, Tanya Baron

Publikováno v: The Lancet. Respiratory Medicine

Background The antibacterial, anti-inflammatory, and antiviral properties of azithromycin suggest therapeutic potential against COVID-19. Randomised data in mild-to-moderate disease are not available. We assessed whether azithromycin is effective in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e7944cd3467f2477596b13badde5575

A Randomised Clinical Trial of Azithromycin Versus Standard Care in Ambulatory COVID-19 – The ATOMIC2 Trial

Autor: Samer Elkhodair, Jonathan Underwood, Vicki S Barber, Phil Moss, Tanya Baron, Lucy Cureton, Ian D. Pavord, Maisha Jabeen, Susan J. Dutton, Daniel Lasserson, Rajendar Garlapati, Joanna Black, Graham Johnson, Fleur Cantle, Sophie B. Morgan, Jennifer L Cane, Ruth Knight, David Clarke, Duncan Richards, Timothy S. C. Hinks, James F. Melhorn, Ariel Wang

Publikováno v: SSRN Electronic Journal.

Background: The antibacterial, anti-inflammatory and antiviral properties of azithromycin suggest therapeutic potential against COVID-19. Randomised data in mild-moderate disease are lacking. We assessed whether azithromycin is effective in reducing

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2eba45c76129f98a905a450437813168
https://doi.org/10.2139/ssrn.3827019